Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
Executive Summary
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
You may also be interested in...
Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.